Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
49
NSPR Quote, Financials, Valuation and Earnings
Last price:
$3.04
Seasonality move
:
-3.62%
Day range:
$2.82 - $3.04
52-week range:
$1.81 - $3.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.89x
P/B ratio:
1.91x
Volume:
11.2K
Avg. volume:
68K
1-year change:
47.09%
Market cap:
$79M
Revenue:
$6.2M
EPS (TTM):
-$0.72
Analysts' Opinion
-
Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, InspireMD has an estimated upside of 56.77% from its current price of $3.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.03.
Fair Value
-
According to the consensus of 0 analysts, InspireMD has 56.77% upside to fair value with a price target of -- per share.
NSPR vs. S&P 500
-
Over the past 5 trading days, InspireMD has overperformed the S&P 500 by 4.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
InspireMD does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
InspireMD has grown year-over-year revenues for 7 quarters straight. In the most recent quarter InspireMD reported revenues of $1.8M.
Earnings Growth
-
InspireMD has grown year-over-year earnings for 0 quarters straight. In the most recent quarter InspireMD reported earnings per share of -$0.16.
Enterprise value:
38.6M
EV / Invested capital:
0.93x
Price / LTM sales:
16.89x
EV / EBIT:
--
EV / Revenue:
5.66x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.88x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.5M
Return On Assets:
-57.43%
Net Income Margin (TTM):
-413.96%
Return On Equity:
-68.55%
Return On Invested Capital:
-68.55%
Operating Margin:
-467.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5.5M | $5.5M | $6.8M | $1.6M | $1.8M | |
| Gross Profit | $1.2M | $1.5M | $1.5M | $438K | $414K | |
| Operating Income | -$17.7M | -$20.3M | -$29.9M | -$5.6M | -$8.5M | |
| EBITDA | -$17.5M | -$20M | -$29.7M | -$5.6M | -$8.4M | |
| Diluted EPS | -$2.27 | -$1.52 | -$0.72 | -$0.15 | -$0.16 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.3M | $40.1M | $24.7M | $46.7M | $46.4M | |
| Total Assets | $15.6M | $42.6M | $28.1M | $50M | $50.5M | |
| Current Liabilities | $2.6M | $3.7M | $4M | $4.7M | $7.3M | |
| Total Liabilities | $4.3M | $5.5M | $6.2M | $6.8M | $9.1M | |
| Total Equity | $11.3M | $37.1M | $21.9M | $43.3M | $41.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.2M | -$15.4M | -$19.3M | -$4M | -$5.7M | |
| Cash From Investing | $6.4M | -$12.2M | $4.4M | $6.4M | -$5.9M | |
| Cash From Financing | -$140K | $37.5M | $16.9M | -- | -$965K | |
| Free Cash Flow | -$15.7M | -$15.7M | -$20.6M | -$4.1M | -$6.1M | |
NSPR
Sector
Market Cap
$79M
$43.9M
Price % of 52-Week High
88.6%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
47.09%
-29.11%
Beta (5-Year)
0.985
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.99
200-day SMA
Buy
Level
$2.57
Bollinger Bands (100)
Buy
Level
2.53 - 2.93
Chaikin Money Flow
Buy
Level
65.3M
20-day SMA
Buy
Level
$2.98
Relative Strength Index (RSI14)
Buy
Level
58.40
ADX Line
Buy
Level
6.95
Williams %R
Neutral
Level
-34
50-day SMA
Buy
Level
$2.69
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
668.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.3597)
Sell
CA Score
(Annual)
Level (-1.7176)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.4712)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Stock Forecast FAQ
In the current month, NSPR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NSPR average analyst price target in the past 3 months is --.
-
Where Will InspireMD Stock Be In 1 Year?
According to analysts, the consensus estimate is that InspireMD share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About InspireMD?
Analysts are divided on their view about InspireMD share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that InspireMD is a Sell and believe this share price will drop from its current level to --.
-
What Is InspireMD's Price Target?
The price target for InspireMD over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NSPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for InspireMD is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NSPR?
You can purchase shares of InspireMD via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase InspireMD shares.
-
What Is The InspireMD Share Price Today?
InspireMD was last trading at $3.04 per share. This represents the most recent stock quote for InspireMD. Yesterday, InspireMD closed at $3.03 per share.
-
How To Buy InspireMD Stock Online?
In order to purchase InspireMD stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
